Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.

ABSTRACT:

Unlabelled

Anti-angiogenic treatment with targeted agents is effective in advanced hepatocellular carcinoma (HCC). This trial evaluated the safety and efficacy of metronomic capecitabine in patients with HCC.

Methods

This single-institution phase II trial included 59 previously untreated patients with advanced HCC and 31 patients resistant to or intolerant of sorafenib. The treatment schedule was capecitabine 500 mg twice daily until progression of disease, unacceptable toxicity level, or withdrawal of informed consent. Progression-free survival (PFS) was chosen as the primary endpoint.

Results

A total of 59 previously untreated and 31 previously treated patients with HCC were enrolled. The first cohort achieved a median PFS of 6.03 months and an overall survival (OS)

SUBMITTER: Brandi G 

PROVIDER: S-EPMC3868418 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature